COMMUNIQUÉS West-GlobeNewswire

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
03/04/2024
Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) SAN DIEGO, April 03, 2024 [...]
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
03/04/2024
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstract Company plans to provide updated interim data, including safety and [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2024
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the [...]
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/04/2024
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
03/04/2024
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/04/2024
CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/04/2024
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered [...]
Nkarta to Participate in Upcoming Investor Conferences
03/04/2024
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two [...]
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
03/04/2024
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has [...]
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
03/04/2024
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)
03/04/2024
Daix (France), Long Island City (New York, United States), le 3 avril 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Two Legend Senior Living® Directors Receive Prestigious Hero Awards From the Texas Assisted Living Association (TALA)
03/04/2024
DALLAS, April 03, 2024 (GLOBE NEWSWIRE) -- Legend Senior Living announced today that Chris Tucker, Health Care Director, Legend of Fort Worth (TX), and Haley Moore, Sales Director, Rock Ridge in Rockwall (TX), are both [...]
Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare
03/04/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 03 avr. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur [...]
UPDATE – Redhook Brewery Announces New “Big Juicy Ballard” IPA and Revives IPA Daze Festival at the Brewlab on 4/20 Weekend
03/04/2024
Redhook Unveils the Latest Addition to Their Thriving Big Ballard family of IPAs, Hitting Shelves this Month SEATTLE, April 03, 2024 (GLOBE NEWSWIRE) -- Redhook Brewery , makers of pure Pacific Northwest ale, and a [...]
NH Nonprofit Heralds New Research Documenting Community Healthcare Workers
03/04/2024
Impacts: More Cancer Screenings, Lower Healthcare Costs Littleton, NH, April 03, 2024 (GLOBE NEWSWIRE) -- North Country Health Consortium, the New Hampshire nonprofit tasked by state officials to increase awareness and [...]
IBEX Shareholders Approve Sale of the Company
03/04/2024
MONTRÉAL, Québec, April 03, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) is pleased to announce that at an annual and special meeting held today, IBEX shareholders [...]
CARBIOS annonce le vif succès de son premier plan d'actionnariat salarié
03/04/2024
CARBIOS annonce le vif succès de son premier plan d'actionnariat salarié Taux de participation record avec 88,49% des collaborateurs éligibles qui ont souscrits à l’opération Un plan comprenant un abondement unilatéral [...]
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
03/04/2024
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024, 6pm CET AB Science SA (Euronext - [...]
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
03/04/2024
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A JUGÉ ADMISSIBLE LA DEMANDE DE RÉEXAMEN DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 3 avril 2024, 18h AB Science SA (Euronext - FR0010557264 - AB [...]

Pages